anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Emerging adults (EAs; ages 18-25) have higher rates of substance use disorders than any other age group and have been hit particularly hard by the opioid crisis. EAs also demonstrate poor adherence to healthcare regimens associated with substance use services, with higher dropout rates and lower service utilization than any other age group. This poor adherence leads to devastating outcomes, including continued substance use, incarceration, and overdose. In addition, high dropout rates contribute to skyrocketing costs to treatment systems as a result of more acute service needs, expensive service utilization, and long waitlists. Cost-effective strategies that are aimed at improving treatment adherence to substance use services and tailored to meet the unique developmental needs of EAs are an imminent need. Further, little is known about risk factors for dropout specific to this age group, hindering effective system responses to this significant problem.

At the same time, substance use service systems are increasingly using peer recovery supports (PRS; i.e., paraprofessionals who have "lived experience" with substance use problems) to bolster treatment outcomes without incurring considerable additional costs. However, services delivered by PRS have not been tailored specifically to reduce EA dropout, and few have been rigorously tested at all. The current study will evaluate an innovative EA-specific dropout prevention enhancement to usual treatment services, delivered by PRS in community-based substance use treatment clinics (Aim 1). The investigators will employ a stepped-wedge cluster randomized design, resulting in each clinic having a longitudinal usual services phase and a longitudinal dropout prevention phase. The two phases will be compared on rates of EA dropout and service utilization using objective data from clinical charts.
Esophageal squamous cell carcinoma (ESCC) is a prevalent and malignant cancer with an unknown pathogenesis and a poor prognosis; therefore, the identification of effective biomarkers and targets is crucial for its diagnosis and treatment. Circular (circ)RNAs are prominent functional biomarkers and therapeutic targets in various diseases, particularly cancer, due to their widespread expression and regulatory mechanisms. Our study aimed to investigate the therapeutic potential of circRNA for ESCC. We identified Hsa_circ_0137111 for the first time as one of the most significantly up-regulated genes in ESCC sequencing and named it circJPH1. The results of the present study demonstrated an enhanced expression of circJPH1 in ESCC tissues. Moreover, circJPH1-knockdown could significantly inhibit the proliferation, migration, and invasion of ESCC cells, while its overexpression promoted these characteristics. In addition, circJPH1 promoted ESCC cell tumor growth in vivo. For the first time, mass spectrometry and RNA pull-down analysis revealed the interaction of X-ray repair cross-complementary 6 (XRCC6) protein with circJPH1, thereby promoting its nuclear translocation. Consequently, the nuclear factor kappa-B (NF-κB) signaling pathway was activated, leading to an up-regulation of HECT and RLD domain containing E3 ubiquitin protein ligase 5 (HERC5), thereby promoting ESCC progression. In summary, the present study elucidated the regulatory impact of circJPH1 on ESCC progression in vitro and in vivo, thereby indicating its potential role in ESCC treatment.
An application of carnosic acid in the preparation of anti-photoaging products. The products contain low-concentration carnosic acid and at least one of pharmaceutically acceptable salts or solvates thereof. The concentration range of the carnosic acid is 0.01-500 nmol/L. The products comprise drugs and skin care products. The skin care products are toner or face cream. Under a specific low concentration, the carnosic acid can produce an anti-aging effect, thereby effectively inhibiting the damage of UVA radiation to skin tissues. The carnosic acid is natural, safe, and non-irritating, can be widely used in anti-photoaging drugs and skin care products, and especially has wide market prospects as a new skin care variety for development.
Metabolic alterations play an essential role in ovarian carcinogenesis. The flexibility of mitochondrial functions facilitates cellular adaptation to the tough environment associated with carcinogenesis. An understanding of the differences in mitochondrial functions in normal ovaries and cancers could provide a basis for further exploration of future mitochondria-based screening, diagnosis, prognostic prediction, and targeted therapy for epithelial ovarian cancers. The main objective of this study was to assess mitochondrial function profiles measured from PBMCs and ovarian tissues of epithelial ovarian cancers in comparison with normal ovaries. A total of 36 patients were recruited for the study, all of whom underwent primary surgical treatment for malignant epithelial ovarian neoplasm. Of these, 20 patients were in the early stage and 16 patients were in the advanced stage. Additionally, 21 patients who had pelvic surgery for benign gynecologic conditions, with normal ovaries incidentally removed, were recruited as controls. At the time of surgery, a blood sample was collected from each participant for PBMC isolation, and ovarian tissue was retained for molecular studies. These studies included the examination of oxidative stress, mitochondrial mass, mitochondrial respiration, mitochondrial reactive oxygen species (ROS), mitochondrial membrane potential (MMP) changes, and mitochondrial swelling. Clinical and histopathological data were also collected and compared between different stages of epithelial ovarian cancers: early-stage (group 1), advanced-stage (group 2), and normal ovaries (group 3). The levels of cellular oxidative stress, mitochondrial mass, and mitochondrial biogenesis in the peripheral blood mononuclear cells (PBMCs) of participants with ovarian cancer were significantly lower than those of the control group. However, the mitochondrial respiratory parameters measured from the PBMCs were similar across all three groups. Furthermore, mitochondrial membrane depolarization and mitochondrial swelling were observed in ovarian tissues of both early-stage and advanced-stage cancer groups. We demonstrated the dynamic nature of mitochondrial ROS production, biogenesis, and respiratory function in response to epithelial ovarian carcinogenesis. The flexibility of mitochondrial functions under diverse conditions may make it a challenging therapeutic target for ovarian cancer.
PROBLEM TO BE SOLVED: To obtain new compounds, useful as an interleukin-1β inhibitor and effective in mitigating inflammations such as chronic articular rheumatism, osteoarthritis, etc. SOLUTION: The compounds are represented by formula I [R1 is a halogen, hydroxyl, a substitutable 1-6C alkoxy, etc.; R2 is a substitutable aryl; Ra and Rb are each H or a 1-6C alkyl; X is O, S or NR; R is H or a 1-6C alkyl; Y is (CH2 )m -Z-(CH2 )n ; Z is O, S, NH, etc.; (m) and (n) are each 0-2], e.g. 2- hydroxymethyl-5-(4-pyridyloxy)benzimidazole. The compounds represented by formula I (X is NR) are obtained by reacting a compound represented by the formula R2 -Y-H with 2-nitro-5-chloroaniline, providing a compound represented by formula II, then catalytically reducing the resultant compound and subsequently reacting the reduced compound with a compound represented by formula III in an acidic medium.  At least one of the compounds represented by formula I can be contained as an active ingredient and formulated as a pharmaceutical preparation in a peroral, a parenteral (intravenous or subcutaneous) and an intranasal administration forms. The daily dose thereof is 0.1-100mg.
In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
Patients receive ascorbic acid IV over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: During the COVID-19 pandemic in China, the proportion of patients with uveitis who were infected with SARS-CoV-2 increased greatly. The impact of SARS-CoV-2 infection on patients with uveitis has not been fully described.
METHODS: A questionnaire on SARS-CoV-2 infection was sent to patients with uveitis to assess ocular and systemic conditions before and after infection. Chi-square analysis and multifactorial regression analysis were used to investigate the associations between each risk factor and the recurrence of uveitis after SARS-CoV-2 infection.
RESULTS: One hundred thirty-nine patients with noninfectious uveitis completed the questionnaire; 114 (82.0%) had COVID-19, and 27 (23.7%) had recurrent or exacerbated uveitis after COVID-19. There was a higher rate of recurrence or aggravation of ocular inflammation in patients who developed severe COVID-19 symptoms (severe group 8/20 vs. nonsevere group 19/94). There were significant differences in the rates of recurrence and aggravation between the two groups of patients who differed in terms of ocular inflammatory activity within 3 months prior to SARS-CoV-2 infection (χ2 = 10.701, P=0.001), as well as in the rates of recurrence and aggravation after cessation of systemic immunomodulatory therapy. After multifactorial regression analysis, patients with active ocular inflammation within 3 months prior to SARS-CoV-2 infection had a greater risk of recurrence or exacerbation of uveitis after COVID-19 (OR=4.298, P=0.002).
CONCLUSION: The degree of ocular inflammatory activity within 3 months prior to SARS-CoV-2 infection may be a major factor influencing the recurrence or exacerbation of uveitis after infection. Interruption of medication should be minimized in patients with unstable inflammatory control.
Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
The present invention relates to a control console automatically planning a personal exercise program in accordance with the physical condition measured through the whole exercise session. The control console is in connection with a heartbeat detector for any fitness equipment. A microprocessor is fitted within the control console and used to record the related change and the interactive relationship of the heartbeat value under exercise parameters of distance, speed, duration and slope during the whole exercise session whenever the operator uses the electric treadmill. Therefore, the current physical state of the certain operator can be exactly detected so as to automatically plan an optimal exercise program according to the personal physical state. In addition, this program will be saved and used for next time when the operator uses the electric treadmill again. Meanwhile, the current physical condition will be measured again so as to renew another optimal exercise program for the certain operator.
The present invention discloses a medicine prepared from polysaccharide sulfate amino acid salts and a preparation method thereof. The medicine is a compound prepared from polysaccharide sulfate polyanion carriers and amino acid salts, wherein the polysaccharide sulfate accounts for 10% to 95% by the weight ratio, and the amino acid accounts for 5% to 90%. The preparation method for the medicine comprises the steps of (1). the extraction of polysaccharide, (2). the preparation of polysaccharide sulfate and (3). the preparation of polysaccharide sulfate amino acid salts. Because the medicine combines the polysaccharide sulfate and the amino acid into salts, the medicine is favorable to the elimination of metallic ions generated in the process of preparing the polysaccharide sulfate and merges the immunity regulation activity of the components and the pharmacological activity of treating chronic nephritis and renal failure, and then a forward direction synergistic effect is generated; thus, the polysaccharide sulfate amino acid salts have stronger protection effect on the renal functions of patients with renal disease than the respective medicinal effect of the polysaccharide sulfate and the natural amino acid. The medicine has the advantages of good water solubility, obvious curative effect, low toxicity and no side effect and is a favorable medicine for treating chronic nephritis and renal failure.
The use of MAOIs intended to treat psychiatric disorders with NORPRAMIN or within 14 days of stopping treatment with NORPRAMIN is contraindicated because of an increased risk of serotonin syndrome. The use of NORPRAMIN within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION).

Starting NORPRAMIN in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION).

NORPRAMIN is contraindicated in the acute recovery period following myocardial infarction. It should not be used in those who have shown prior hypersensitivity to the drug. Cross-sensitivity between this and other dibenzazepines is a possibility.
A bubble type waterless shampoo composition. 0.1 to 5 wt % of potassium cocoyl hydrolyzed collagen and 0.01 to 2 wt % of palmitoyl oligopeptide as natural surfactants. 0.1 to 7 wt % of cocamidopropyl betaine as an amphoteric ion. 0.01 to 0.8 wt % of a citric acid as an organic acid. 0.1 to 4 wt % of sodium carbonate as inorganic salt. 0.01 to 0.5 wt % of  origanum vulgare  leaf oil. 0.01 to 0.6 wt % of a gallic acid. 0.01 to 3 wt % of glycerin. The rest of aqua water having a function of a solvent made by refining tap water through distilling or ion-exchange resin ion.
500,266. Eye-lotion tablets. TAYLOR. G. W. Aug. fi, 1937, No. 21700. [Class 81 (i)] Eye-lotion tablets soluble in water are obtained by triturating methylene blue with a mixture of antiacid and antiseptic powders (sodium bicarbonate and sodium borate), intimatety incorporating in succession acriflavin, adrenalin chloride, and citric acid, adding the resultant mixture in stages to a solution of menthol in a plurality of essential oils which have been mixed together at a temperature not exceeding 20‹ C., and forming tablets from the final mixture. Sodium chloride, a local. anµsthetic such as procaine or benzocaine, aluminium sulphate, and sodium benzoate may be included in the mixture of solid materials, and methyl salicylate in the liquids. The relative proportions of the ingredients and the essential oils to be used are specified.
Study agent: 2-deoxy-2-\[18F\]fluoro-D-glucose (FDG). Fluoro-D-glucose-positron Emission Tomography: Participants will undergo a PET-CT scan with Fluoro-D-glucose-labeled (FDG-labeled) red blood cells (RBCs) within 2 weeks of obtaining an echocardiogram prior to start of chemotherapy. A repeat FDG-RBC PET-CT scan will be completed within two weeks of obtaining their follow-up echocardiogram to determine post-therapy cardiac ejection fraction. If the participant has an echocardiogram obtained prior to completion of chemotherapy, an attempt will be made to obtain a FDG-RBC PET-CT scan within two weeks of the echocardiogram.
OBJECTIVE: To analyze the clinical characteristics of scar cancer ulcer wound of head and face, and to investigate its diagnosis and treatment.
METHODS: The clinical data of 14 patients with head and facial scar cancer ulcer wounds who met the selection criteria and admitted between January 2021 and March 2022 were retrospectively analyzed. There were 8 males and 6 females. The age of onset ranged from 21 to 81 years with an average age of 61.6 years. The incubation period ranged from 1 month to 70 years, with a median of 4 years. Site of the disease included 7 cases of head, 6 cases of maxillofacial region, and 1 case of neck region. Injury factors included trauma in 5 cases, scratch in 5 cases, scalding in 2 cases, burn in 1 case, and needle puncture in 1 case. Pathological results showed squamous cell carcinoma in 9 cases, basal cell carcinoma in 3 cases, sebaceous adenocarcinoma in 1 case, papillary sweat duct cystadenoma combined with tubular apocrine sweat gland adenoma in 1 case. There was 1 case of simple extensive tumor resection, 1 case of extensive tumor resection and skin grafting repair, 7 cases of extensive tumor resection and local flap repair, and 5 cases of extensive tumor resection and free flap repair.
RESULTS: All the 14 patients were followed up 16-33 months (mean, 27.8 months). Two patients (14.29%) had scar cancer ulcer wound recurrence, of which 1 patient recurred at 2 years after 2 courses of postoperative chemotherapy, and was still alive after oral traditional Chinese medicine treatment. One patient relapsed at 1 year after operation and died after 2 courses of chemotherapy. One patient underwent extensive resection of the left eye and periocular tumor and the transfer and repair of the chimaeric muscle axial flap with the perforating branch of the descending branch of the left lateral circumflex femoral artery, but the incision healing was poor after operation, and healed well after anti-infection and debridement suture. The wounds of other patients with scar cancer ulcer did not recur, and the wounds healed well.
CONCLUSION: Scar cancer ulcer wound of the head and face is common in the middle-aged and elderly male, and the main pathological type is squamous cell carcinoma. Local extensive resection, skin grafting, or flap transfer repair are the main treatment methods. Early active treatment of wounds after various injuries to avoid scar repeated rupture and infection is the foundamental prevention of scar cancer.
PURPOSE:To provide an antitumor agent containing cell and cell component of Bordetella bronchiseptica as a main component. CONSTITUTION:The objective agent contains the cells or cell component of Bordetella bronchiseptica (B.b) as an active component. The culture medium for the growth of B.b is selected from Bordet-Gengou medium, brain heart infusion medium and a medium produced by adding serum of cattle, horse, etc., to the above medium. B.b is inoculated in the medium and cultured e.g. at 37 deg.C for 50hr. The objective antitumor agent contains, as an active component, the bacterial cell collected from the culture product and washed or a bacterial cell component such as whole cell wall, etc., produced by disintegrating the cell by ultrasonic treatment, etc., and centrifuging the product. The agent can be used in the form of a freeze-dried preparation containing a protecting agent (e.g. sucrose). It exhibits excellent regression effect against tumor and strong antitumor activity against implantable tumor.
Patients will receive a simulated continuous femoral nerve block at the level of the adductor canal for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
While treatment with L-T4 after TH-withdrawal is widely used in DTC patients to suppress TSH and improve hypothyroid symptoms, the value of L-T3 has not been evaluated in this context. Lifelong monotherapy with L-T3 should not be preferred over L-T4 yet, short-term use of L-T3 to initiate TH-supplementation can be safely implemented. We hypothesize that initial treatment with L-T3 can have a more rapid effect on TSH-levels and earlier relieve of hypothyroid symptoms resulting in a better QoL. To evaluate TH-supplementation with L-T3, we will conduct a prospective cohort study comparing the initiation of TH-supplementation after TH-withdrawal in two cohorts of DTC patients: patients treated in the University Medical Centre Groningen (UMCG) receiving L-T3 and patients treated in the Radboud University Medical Centre (Radboud UMC) receiving L-T4. We will compare potency to suppress TSH, effect on QoL and effects on thyroid- and cardiovascular parameters. Patients (18-75 years) diagnosed with high-risk DTC treated in the UMCG or Radboud UMC and receiving THST with L-T3 or L-T4 after TH-withdrawal will be eligible for inclusion. The primary objective is to compare the proportion of patients reaching target TSH-levels after two weeks of substitution with L-T3 or L-T4.

Secondary objectives are to compare the effects of L-T3 and L-T4 in the first 6 months of treatment on serum thyroid parameters TSH and Tg, quality of life, weight, and cardiovascular parameters
Unilateral nephrectomy, a procedure reducing kidney mass, triggers a compensatory response in the remaining kidney, increasing its size and function to maintain a normal glomerular filtration rate (GFR). Recent research has highlighted the role of extracellular vesicles (EVs) in renal physiology and disease, although their involvement in unilateral nephrectomy has been underexplored. In this study, unilateral nephrectomy was performed on young mice, and urinary extracellular vesicles (uEVs) characterization and cargo were analyzed. Kidney volume increased significantly post-nephrectomy, demonstrating compensatory hypertrophy. Serum creatinine, cystatin C, and urinary electrolytes concentrations were similar in both nephrectomized and control groups. Western blot analysis revealed upregulation of sodium-glucose cotransporter 2 (SGLT2) and sodium chloride cotransporter (NCC), and downregulation of sodium‑potassium-chloride co-transporter (NKCC2) and epithelial sodium channel (ENaC) in the nephrectomized group. Metabolomic analysis of uEVs showed an enrichment of certain metabolites, including citrate and stachydrine. Interestingly, uEVs from the nephrectomized group demonstrated a protective effect, downregulating signal transducer and activator of transcription 3 (STAT3) and reducing reactive oxygen species (ROS) in renal proximal cells, compared to uEVs from the control group. This study suggests that uEVs contain bioactive components capable of inducing protective, anti-inflammatory, anti-fibrinolytic, and antioxidative effects in renal cells. These findings contribute to our understanding of uEVs' role in renal compensatory mechanisms after unilateral nephrectomy and may hold promise for future therapeutic interventions in renal diseases.
Stimulation sessions will be carried out using a neuroConn DC stimulator (Ilmeneau, GmbH). The stimulator is connected to two rubber electrodes which are placed inside two sponge electrodes soaked in a saline solution (0.9% NaCl), respectively. The active electrode (cathode) is 5×5 cm and placed on the sagittal midline at 15% of the distance between inion and nasion anterior to Cz (vertex), using the International 10-20 EEG System, to target the bilateral presupplementary motor area (pre-SMA). The reference electrode is 5×7 cm and placed on the lateral surface of the patient's right deltoid. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
PURPOSE:To obtain a dental ceramic material capable of providing a dental ceramic molded body having high strength and low shrinkage and solving mutually contradictory problems of the strength and shrinkage factor. CONSTITUTION:The objective dental ceramic material is characterized by comprising ceramic powder and aluminosilicate glass powder as principal ingredients, 95-65 pts.wt. ceramic powder mixed with 5-35 pts.wt. aluminosilicate glass powder based on 100 pts.wt. total amount of both the powder and the aluminosilicate glass powder having a composition of 45-65wt.% SiO2, 5-15wt.% B2O3, 5-25wt.% Al2O3, 11-30wt.% CaO, 0.1-5wt.% MgO and 0-5wt.% total amount of Na2O and k2O. In this case, the aluminosilicate glass powder preferably has a spherical shape.
Arm 1 will receive the aerobic prescription exercise intervention. As this is a feasibility and safety study, there will not be a second arm.